Cerebrolysin is a standardised mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue, manufactured as a prescription neurotrophic medicine. It is given by intravenous or intramuscular injection and has been researched primarily for ischaemic stroke recovery, dementia and traumatic brain injury. It is approved as a medicine in a number of European and Asian countries but is not approved by the US FDA, and the clinical evidence remains mixed. At Menscape Clinic in Bangkok, it is considered only after medical assessment and is provided under physician supervision.
/)
Medically reviewed by Dr. Tuksaorn Suriyakan (Ping), Anti-Aging & Regenerative Medicine Physician
8 years of experience
Our solutions for Cognitive Health
Indications evaluated in research, listed in order of current evidence weight. Suitability is determined case-by-case.
Cerebrolysin is a prescription neuropeptide preparation made from purified pig brain proteins that are enzymatically broken down into a standardised mixture of small peptides and free amino acids. First developed in the mid-20th century and refined by an Austrian pharmaceutical manufacturer, it is registered as a medicine in over 50 countries across Europe, Asia and Latin America, where it is used mainly for stroke, dementia and brain injury. It is not approved by the US FDA. Because it is a biologically derived injectable medicine rather than a simple supplement, it should only be used under medical supervision after individual assessment, which is the approach taken at Menscape Clinic in Bangkok.
/)
Cerebrolysin's peptide fragments are believed to act somewhat like the body's own neurotrophic factors, the signalling molecules that help neurons survive, grow and form connections. In laboratory and animal research it has been studied for effects such as supporting neuron survival, influencing how amyloid precursor protein is processed, encouraging the formation of new neurons, and reducing markers of neuroinflammation. These are proposed mechanisms drawn largely from preclinical work; the degree to which they produce meaningful clinical benefit in people remains an open scientific question, which is why any claims about results are kept cautious.
/)
In countries where it is registered, Cerebrolysin is typically considered in a neurological context, for example as part of supervised stroke rehabilitation, certain dementia presentations, or recovery after brain injury, always alongside standard care rather than instead of it. It is not a lifestyle nootropic or a general cognitive enhancer with established benefit, and it is not appropriate for everyone. Any consideration of Cerebrolysin at Menscape Clinic begins with a clinical conversation about your history, current medications and goals, so that a physician can judge whether it is reasonable to discuss at all and explain the uncertainty in the evidence.
/)
At Menscape Clinic in Bangkok, Cerebrolysin is never offered as an off-the-shelf product. It starts with a medical consultation and review of your health background. Where a physician judges it appropriate, it is administered by intravenous or intramuscular injection under clinical supervision, typically as a short course rather than a single dose, with monitoring for tolerability. Because Menscape serves an international and English-speaking patient base, the team will walk you through what is and is not known about the evidence, the regulatory status, the practicalities for visiting patients, and any follow-up, so you can make an informed decision.
/)
Every Cerebrolysin protocol starts with a full medical consultation and history review.
Prescriptions are filled by a licensed compounding pharmacy partner, not over-the-counter.
Follow-up consultations every four to six weeks to assess response and safety.
We frame Cerebrolysin as a research-stage option and prescribe only when clinically appropriate.
Cerebrolysin is not approved by the US FDA for any use. It is, however, registered and approved as a prescription medicine in more than 50 countries across Europe, Asia and Latin America, where it is used under medical supervision. At Menscape Clinic in Bangkok it is handled as a prescription medicine and only provided after a physician assessment, not sold directly to the public.
In clinical studies the most commonly reported effects have been injection-site reactions, gastrointestinal symptoms such as nausea, and occasional dizziness or agitation. One Cochrane review of stroke trials also noted a signal of more non-fatal serious adverse events, so it is not free of risk. As an injectable biologically derived medicine, it should only be given under medical supervision after screening for allergies and other conditions, which is how it is approached at the clinic.
Its largest body of research is in acute ischaemic stroke recovery, followed by vascular and Alzheimer's-type dementia and traumatic brain injury. Across these areas the evidence is genuinely mixed: some trials and meta-analyses report modest short-term signals on neurological or cognitive scores, while major reviews have found no clear benefit on outcomes like survival. It is best understood as a researched but unproven option, not a guaranteed treatment.
There is little reliable human evidence that Cerebrolysin improves cognition in healthy adults. The clinical research has focused on people with stroke, dementia or brain injury, not on general cognitive enhancement. Anyone considering it for everyday memory or focus should know that this use is not supported by strong data and would be off-label and experimental.
Cerebrolysin is administered by injection, either intravenously (often as a short infusion) or intramuscularly, rather than as a tablet, because the peptides would not survive digestion. In research and clinical practice it is typically used as a course over several days or weeks rather than a single dose. At Menscape Clinic this is done under clinical supervision following a consultation.
Cerebrolysin may be discussed at Menscape Clinic, but only after a medical consultation, and it is never guaranteed. The team works regularly with English-speaking and international patients and can explain the evidence, the regulatory status, scheduling for a short visit, and any follow-up before anything is decided. The starting point is always a conversation with a physician about whether it is appropriate for you.
/)
Dr. Tuksaorn (Dr. Ping) is an anti-aging and regenerative medicine physician with over 8 years of experience, focused on evidence-based wellness and personalized health programs that combine modern medical science with individualized care.
/)
/)
/)
/)
/)